Global Exocrine Pancreatic Insufficiency Market, By Diagnosis (Imaging Tests, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1)), Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Others), Drugs (Creon, Zenpep, Pancreaze, Ultresa, Viokace, Others), Symptoms (Abdominal Pain, Constipation, Diarrhea, Fatty stools, Weight Loss, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Exocrine pancreatic insufficiency is caused by pancreatitis, cystic fibrosis, and other pancreatic diseases (EPI). EPI patients lack the pancreatic (digestive) enzymes needed to break down foods and absorb nutrients. It has the potential to cause malnutrition. PERT (pancreatic enzyme replacement treatment) may be beneficial. In EPI, pancreatic replacement therapy is a well-established treatment option that helps to reduce malabsorption and malnutrition. Lipase is responsible for fat digestion, protease is responsible for protein digestion, and amylase is responsible for starch digestion in the body. The USFDA approved the following pancreatic enzyme products (PEPs) for EPI treatment in 2009: Zenpep and Creon, Viokace and Ultresa in 2012, Pancreaze in 2010, and Pertzye in 2012.
Data Bridge Market Research analyses that the exocrine pancreatic insufficiency market was valued at USD 2.27 billion in 2021 and is expected to reach USD 3.75 billion by 2029, registering a CAGR of 6.50% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Imaging Tests, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1)), Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Others), Drugs (Creon, Zenpep, Pancreaze, Ultresa, Viokace, Others), Symptoms (Abdominal Pain, Constipation, Diarrhea, Fatty stools, Weight Loss, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
AstraZeneca (UK), Johnson & Johnson Private Limited (US), AbbVie Inc. (US), Allergan (Ireland), Nordmark Arzneimittel GmbH & Co. KG (Germany), Digestive Care, Inc. (US), Cilian AG (Germany), Anthera Pharmaceuticals, Inc. (US), Eli Lilly and Company (US), Takeda Pharmaceutical Company Limited (Japan), Horizon Therapeutics plc (Ireland), BioMarin (US), Alexion Pharmaceuticals, Inc. (US), Sanofi (France), Abbott (US)
|
|
Market Opportunities
|
|
Market Definition
Exocrine pancreatic insufficiency (EPI) is a condition caused by a lack of exocrine pancreatic enzymes, which causes maldigestion or inability to digest food. EPI has been linked to a variety of pancreatic disorders and syndromes, including cystic fibrosis, chronic pancreatitis, Shwachman–Diamond syndrome, and others. Pancreatic enzyme replacement therapy (PERT) is the first-line treatment in individuals with exocrine pancreatic insufficiency. Treatment for pancreatic exocrine insufficiency with PERT is both safe and effective. Pancrease, Pertzye, Creon, Zenpep and Viokace are some of the medications utilized in PERT. Patients with exocrine pancreatic insufficiency are unable to effectively digest proteins, lipids, and carbohydrates in their food, resulting in poor nutritional absorption.
Exocrine Pancreatic Insufficiency Market Dynamics
Drivers
- Rise in the prevalence of chronic pancreatitis (CP) and cystic fibrosis (CF)
The surging prevalence of chronic pancreatitis (CP) and cystic fibrosis (CF) is anticipated to propel the exocrine pancreatic insufficiency market's growth rate during the forecast period of 2022-2029. The most prevalent cause of EPI in adults is chronic pancreatitis (CP), which is followed by cystic fibrosis (CF). CF is a chronic disease caused by an inherited genetic disorder that affects the lungs, digestive, and reproductive systems. Exocrine pancreatic insufficiency affects around 50% of cystic fibrosis new-borns at birth, with another 25% developing it within six months. Exocrine pancreatic insufficiency strikes another 15% of people during childhood or early adulthood.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of exocrine pancreatic insufficiency market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Rising prevalence of diabetes
The growing prevalence of diabetes is projected to be a major driver of the market. Diabetes is on the rise due to sedentary lifestyles and unhealthy diets. According to a study published in Diabetes Research and Clinical Practice, the global diabetes frequency was 463 million in 2019 and is expected to reach 578 million by 2030. As per a study published in Current Diabetes Reports, type 1 diabetes has a higher prevalence of exocrine pancreatic insufficiency (EPI) than type 2 diabetes.
Furthermore, growing government initiatives to spread awareness will ehance the market’s growth rate. Sedentary lifestyle of people and surging geriatric population will result in the expansion of exocrine pancreatic insufficiency market. Along with this, favourable reimbursement policies will enhance the market's growth rate.
Opportunities
- Rising number of research and development activities
The market's growth is fueled by an increase in the number of research and development activities. This will create new market opportunities. To meet the growing need for new treatments, leading companies are investing in research and development to develop and introduce new exocrine pancreatic insufficiency medicines, increasing market growth. AzurRx, for instance, is developing MS1819, a yeast-derived lipase that has been designed to have higher enzymatic activity than current treatments.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will provide beneficial opportunities for the exocrine pancreatic insufficiency market growth.
Restraints/Challenges
- Strict food and drug administration (FDA) regulation
Due to potential bad effects and ineffectiveness, various drug regulatory bodies, such as the US Food and Drug Administration (FDA), have advised producers to get regulatory authorization before marketing their products. The FDA's strict requirements have made pancrelipase product approval challenging. This is limiting the market expansion.
On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. Developing economies' lack of healthcare infrastructure and dearth of skilled professionals will challenge the exocrine pancreatic insufficiency market. Additionally, side effects associated with drugs and the lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This exocrine pancreatic insufficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the exocrine pancreatic insufficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Exocrine pancreatic insufficiency market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Global Exocrine Pancreatic Insufficiency Market Scope
The exocrine pancreatic insufficiency market is segmented on the basis of diagnosis, treatment, drugs, symptoms, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Imaging Tests
- CT scan
- Abdominal ultrasound
- Others
- Secretin Pancreatic Function Test
- Fecal Fat Test
- Fecal Elastase Test (FE-1)
Treatment
- Nutritional Management
- Pancreatic Enzyme Replacement Therapy (PERT)
- Others
Drugs
- Creon
- Zenpep
- Pancreaze
- Ultresa
- Viokace
- Others
Symptoms
- Abdominal Pain
- Constipation
- Diarrhea
- Fatty stools
- Weight Loss
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Exocrine Pancreatic Insufficiency Market Regional Analysis/Insights
The exocrine pancreatic insufficiency market is analysed and market size insights and trends are provided by country, diagnosis, treatment, drugs, symptoms, end-users and distribution channel as referenced above.
The countries covered in the exocrine pancreatic insufficiency market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the exocrine pancreatic insufficiency market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing number of research and development activities will further propel the market’s growth rate in this region. Additionally, presence of major key players and rising healthcare expenditure will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period of 2022 to 2029 due to growing prevalence of diabetes in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Exocrine Pancreatic Insufficiency Market Share Analysis
The exocrine pancreatic insufficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to exocrine pancreatic insufficiency market.
Some of the major players operating in the exocrine pancreatic insufficiency market are:
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- AbbVie Inc. (US)
- Allergan (Ireland)
- Nordmark Arzneimittel GmbH & Co. KG (Germany)
- Digestive Care, Inc. (US)
- Cilian AG (Germany)
- Anthera Pharmaceuticals, Inc. (US)
- Eli Lilly and Company (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Horizon Therapeutics plc (Ireland)
- BioMarin (US)
- Alexion Pharmaceuticals, Inc. (US)
- Sanofi (France)
- Abbott (US)
SKU-